Intragastric balloon for obesity treatment: results of a multicentric evaluation for balloons left in place for more than 6 months

Genco, Alfredo; Maselli, Roberta; Frangella, Francesca; Cipriano, Massimiliano; Forestieri, Pietro; Daniela, Delle Piane; Furbetta, Francesco; Micheletto, Giancarlo; Ciampaglia, F; Paola, Granelli; Zilli, M.; Lorenzo, Michele; Giorgio, Di; Guarneri, Domenico; Redler, Adriano

doi:10.1007/s00464-014-3957-0

Cited by 22 publications

(11 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Commonly used gastric balloons are designed to remain in the stomach for a maximum duration of 6 months. Although a multi-centric Italian study reported that BIB ® treatment up to 14 months was found to achieve greater weight loss than the BIB ® in situ for 6 months without complications [9], early gastric balloon extraction is vital to minimize complications [10]. Balloons retained for more than 6 months found to be associated with higher rates of balloon rupture, displacement and occasional intestinal obstruction [10].…”

Section: Discussionmentioning

confidence: 99%

Laparoscopic removal of gastric balloon after failure of endoscopic retrieval

Sharroufna

Hassan

Alabdrabalmeer

et al. 2019

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Laparoscopic removal of gastric balloon after failure of endoscopic retrieval

Sharroufna

Hassan

Alabdrabalmeer

et al. 2019

International Journal of Surgery Case Reports

View full text Add to dashboard Cite

show abstract

“…In cases of intolerance, the IGB can be removed earlier [ 8 ]. However, prolonged IGB therapy up to 14 months has been reported to maintain satiety and improve weight loss, without any safety issues [ 9 ].…”

Section: Discussionmentioning

confidence: 99%

An Autopsy Case of Misdiagnosed Wernicke’s Syndrome after Intragastric Balloon Therapy

Vellante

Carnevale

D’Ovidio

2018

Case Reports in Gastrointestinal Medicine

View full text Add to dashboard Cite

Intragastric balloon (IGB) therapy is a widely used technique to counter obesity, and it is known to be safe and effective. Although there can be a high rate of side effects following IGB therapy, most are self-healing and they are mainly accommodative in nature. Few cases of Wernicke's syndrome under IGB therapy have been described in the literature, and to the best of our knowledge, none have been fatal. We present here a case of a 51-year-old woman who underwent IGB therapy over 8 months. Late diagnosed Wernicke's syndrome that first appeared as lower limb neuropathy progressively immobilized the patient, until she required bed rest. Finally, a major complication of pneumonia caused her death. Wernicke's syndrome has been mainly related to bariatric surgery techniques, but it must also be linked to IGB therapy (and also to other restrictive weight-loss interventions). As the use of IGB therapy spreads, the literature must alert physicians to this complication. Wernicke's syndrome is a severe but reversible condition when diagnosed and treated early.

show abstract

“…It has been used in other countries for many years before being approved by FDA for use in the United States in 2015. Based on a large meta-analysis of 17 studies, the percentage of excess weight loss (%EWL) with the Orbera IGB at 12 mo was 25.44% and total body weight loss (%TBWL) was 12.3% 13.16%, and 11.27% at 3, 6, and 12 mo after implantation, respectively[13,14]. In a recent multicenter, randomized, open-label clinical trial, 255 adults with a BMI of 30-40 kg/m 2 were treated and outcomes were assessed up to 12 mo.…”

Section: Space Occupying Techniquesmentioning

confidence: 99%

New Era: Endoscopic treatment options in obesity—a paradigm shift

Glass

Chaudhry

Zeeshan

et al. 2019

WJG

View full text Add to dashboard Cite

The prevalence of obesity continues to rise, and along with it comes a multitude of health-related consequences. The healthcare community has consistently struggled with providing treatment options to obese patients, in part due to the reluctance of patients in pursuing the more effective (yet invasive) surgical approaches such as sleeve gastrectomy and Rou-en-Y gastric bypass. On the other hand, the less invasive approach such as lifestyle/behavioral interventions and pharmacotherapy (Orlistat, Phenteramine, Phentermine/Topiramate, Locaserin, Naltrexon/Buproprion, and Liraglutide) have very limited efficacy, especially in the morbidly obese patients. Despite our best efforts, the epidemic of obesity continues to rise and pose enormous costs on our healthcare system and society. Bariatric endoscopy is an evolving field generated to combat this epidemic through minimally invasive techniques. These procedures can be performed in an ambulatory setting, are potentially reversible, repeatable, and pose less complications than their invasive surgical counterparts. These modalities are designed to alter gut metabolism by means of space occupation, malabsorption, or restriction. In this review we will discuss different bariatric endoscopic options (such as intragastric balloons, endoscopic sleeve gastroplasty, endoscopic aspiration therapies and gastrointestinal bypass sleeves), their advantages and disadvantages, and suggest a new paradigm where providers may start incorporating this modality in their treatment approach for obese patients.

show abstract

Intragastric balloon for obesity treatment: results of a multicentric evaluation for balloons left in place for more than 6 months

Abstract: Extending the duration of BIB(®) use up to 14 months safely maintains weight loss and satiety with greater results than that up to 6 months, without complications.

Cited by 22 publications

References 14 publications

Laparoscopic removal of gastric balloon after failure of endoscopic retrieval

Laparoscopic removal of gastric balloon after failure of endoscopic retrieval

An Autopsy Case of Misdiagnosed Wernicke’s Syndrome after Intragastric Balloon Therapy

New Era: Endoscopic treatment options in obesity—a paradigm shift

Contact Info

Product

Resources

About